MMJ PhytoTech Limited (
Importantly, MMJ can advise that it is actively assessing a number of Australian-based strategic investment opportunities in the medicinal cannabis sector, aimed at further leveraging the Company's global distribution networks and cannabis cultivation expertise.
Further details will be provided on these potential strategic investment opportunities in the near-term.
In addition, MMJ through its 59%-ownership in TSX-V listed Harvest One Cannabis Inc. (
Satipharm CBD capsules are manufactured by Satipharm AG (wholly-owned by Harvest One) and are currently sold throughout key regulated cannabis markets globally.
Commenting on the Federal Government's decision, MMJ's Managing Director, Andreas Gedeon, said:
"We are very encouraged by the Federal Government's plans to fast-track the growth of the Australian medicinal cannabis sector, with this latest development providing local cannabis producers with the required framework to compete on a global scale.
"Prior to this development, the Board had been actively assessing a number of Australianbased investment opportunities to complement MMJ's existing asset base, and this latest legislative decision has provided the Company with a great deal of confidence to deploy additional capital into the Australian sector."
About Harvest One Cannabis Inc.
Harvest One Cannabis Inc. (
About MMJ Group Holdings Ltd
MMJ Group Holdings Ltd (ASX:MMJ) is a global cannabis investment company. MMJ owns a portfolio of minority investments and aims to invest across the full range of emerging cannabis-related sectors including healthcare, technology, infrastructure, logistics, processing, cultivation, equipment and retail. For MMJ's latest investor presentation and news, please visit: http://www.mmjphytotech.com.au/investors/
Contact
Investor and Media Enquiries:Jason Conroy
Chief Executive Officer
T: +61-2-8098-0819
E: info@mmjgh.com.au
Related Companies
Related Industry Topics: